The STML chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the STML chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The STML stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View STML Detailed Price Forecast - CNN Money||View STML Detailed Summary - Google Finance|
|View STML Detailed Summary - Yahoo! Finance||View STML Stock Research & Analysis - Zacks.com|
|View STML Trends & Analysis - Trade-Ideas||View STML Major Holders - Barrons|
|View STML Call Transcripts - NASDAQ||View STML Breaking News & Analysis - Seeking Alpha|
|View STML Annual Report - CompanySpotlight.com||View STML OTC Short Report - OTCShortReport.com|
|View STML Fundamentals - TradeKing||View STML SEC Filings - Bar Chart|
|View Historical Prices for STML - The WSJ||View Performance/Total Return for STML - Morningstar|
|View the Analyst Estimates for STML - MarketWatch||View the Earnings History for STML - CNBC|
|View the STML Earnings - StockMarketWatch||View STML Buy or Sell Recommendations - MacroAxis|
|View the STML Bullish Patterns - American Bulls||View STML Short Pain Metrics - ShortPainBot.com|
|View STML Stock Mentions - StockTwits||View STML Stock Mentions - PennyStockTweets|
|View STML Stock Mentions - Twitter||View STML Investment Forum News - Investor Hub|
|View STML Stock Mentions - Yahoo! Message Board||View STML Stock Mentions - Seeking Alpha|
|View Insider Transactions for STML - SECform4.com||View Insider Transactions for STML - Insider Cow|
|View STML Major Holdings Summary - CNBC||View Insider Disclosure for STML - OTC Markets|
|View Insider Transactions for STML - Yahoo! Finance||View Institutional Holdings for STML - NASDAQ|
|View STML Stock Insight & Charts - FinViz.com||View STML Investment Charts - StockCharts.com|
|View STML Stock Overview & Charts - BarChart||View STML User Generated Charts - Trading View|
Read This Before Buying Stemline Therapeutics, Inc. (NASDAQ:STML) Shares
Posted on Monday January 21, 2019
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock
Posted on Friday January 18, 2019
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the closing of a previously announced underwritten public offering of 10,222,222 shares of its common stock, which included the exercise in full of the option to purchase 1,333,333 additional shares, at a price of $9.00 per share. J.P. Morgan Securities LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC acted as co-lead managers and Roth Capital Partners, LLC, ThinkEquity, a division of Fordham Financial Management, Inc., A.G.P./Alliance Global Partners, National Securities Corporation, and Aegis Capital Corp. acted as co-managers for the offering.
Stemline Therapeutics (STML) in Focus: Stock Moves 9.5% Higher
Posted on Wednesday January 16, 2019
Stemline Therapeutics (STML) shares rose nearly 10% in the last trading session, amid huge volumes.
Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock
Posted on Tuesday January 15, 2019
Stemline Therapeutics, Inc. (STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing innovative oncology therapeutics, today announced the pricing of an underwritten public offering of 8,888,889 shares of its common stock at a price of $9.00 per share, with expected gross proceeds to Stemline of $80 million. Stemline has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co., LLC are acting as co-lead managers and Roth Capital Partners, LLC, ThinkEquity, a division of Fordham Financial Management, Inc., A.G.P./Alliance Global Partners, National Securities Corporation, and Aegis Capital Corp. are acting as co-managers for the offering.